All In Biotech

Drug Trial Radar · NCT02576795

Gene Therapy Study in Severe Haemophilia A Patients (270-201)

A Phase 1/2, Dose-Escalation, Safety, Tolerability and Efficacy Study of Valoctocogene Roxaparvovec, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A

Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

15

Actual

Start

Sep 28, 2015

Primary completion

Feb 14, 2024

Study completion Feb 14, 2024

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Oct 15, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted by BioMarin Pharmaceutical Inc. as an open label, dose escalation study in order to determine the safety and efficacy of valoctocogene roxaparvovec (an Adenovirus-Associated Virus based gene therapy vector in participants with severe haemophilia A.

Conditions

  • Severe Haemophilia A

Interventions

  • valoctocogene roxaparvovecBiological

    Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Severe Hemophilia A

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse EventsTime frame: Approximately up to 7 years after dosing
  2. Number of Participant With Median FVIII Activity Levels >= 5 IU/dL Using Chromogenic Substrate Assay (CSA)Time frame: Week 13-16 post-BMN 270 infusion
  3. Median FVIII Activity as Measured by Chromogenic Substrate Assay During Week 13-16 Post-BMN 270 InfusionTime frame: Week 13-16 post-BMN 270 infusion

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Queen Elizabeth Hospital Birmingham

    Birmingham, United Kingdom

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • St. Thomas' Hospital

    London, United Kingdom

  • The Royal London Hospital

    London, United Kingdom

  • University Hospital Southampton NHS Foundation Trust

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.